Heyman Richard A. 4
4 · Enliven Therapeutics, Inc. · Filed Oct 22, 2024
Insider Transaction Report
Form 4
Heyman Richard A.
Director
Transactions
- Sale
Common Stock
2024-10-18$30.00/sh−817$24,512→ 123,673 total - Sale
Common Stock
2024-10-18$30.00/sh−753$22,592→ 27,165 total(indirect: See footnote)
Holdings
- 37,407(indirect: See footnote)
Common Stock
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023.
- [F2]This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member.
- [F4]The shares are held of record by the Richard A. Heyman and Anne E. Daigle Trust, dated November 1, 2016 for which the Reporting Person serves as trustee.